Atomic Alchemy is developing a small fast reactor specifically for medical and industrial isotope production — a unique SMR application targeting the multi-billion dollar radioisotope market currently dependent on ageing research reactors. Selected for the DOE Reactor Pilot Programme in August 2025 targeting criticality by July 4, 2026. Atomic Alchemy's reactor produces radioisotopes used in cancer treatment, cardiac imaging, and industrial non-destructive testing — addressing a critical national security and healthcare supply chain vulnerability.
US Department of Energy, private investors